Valence8 US LP Invests $310,000 in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Valence8 US LP acquired a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,188 shares of the company’s stock, valued at approximately $310,000. Tyra Biosciences accounts for about 0.1% of Valence8 US LP’s investment portfolio, making the stock its 27th biggest position.

A number of other institutional investors also recently bought and sold shares of TYRA. Charles Schwab Investment Management Inc. raised its position in shares of Tyra Biosciences by 2.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock valued at $4,085,000 after buying an additional 3,792 shares during the period. Jennison Associates LLC increased its stake in Tyra Biosciences by 5.9% during the third quarter. Jennison Associates LLC now owns 158,187 shares of the company’s stock worth $3,719,000 after acquiring an additional 8,837 shares during the last quarter. Quest Partners LLC acquired a new position in shares of Tyra Biosciences in the 3rd quarter valued at $491,000. Oppenheimer & Co. Inc. grew its holdings in shares of Tyra Biosciences by 9.0% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 76,806 shares of the company’s stock worth $1,806,000 after purchasing an additional 6,318 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Tyra Biosciences during the 3rd quarter worth about $311,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on TYRA. Wedbush reaffirmed an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research report on Friday, October 25th. Piper Sandler began coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price for the company. HC Wainwright cut their target price on Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Oppenheimer raised their price target on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. Finally, Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $22.00 to $31.00 in a report on Friday, October 18th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $31.00.

Insider Buying and Selling

In related news, CEO Todd Harris sold 5,698 shares of Tyra Biosciences stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $24.31, for a total transaction of $138,518.38. Following the completion of the transaction, the chief executive officer now directly owns 1,496,729 shares of the company’s stock, valued at approximately $36,385,481.99. The trade was a 0.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Nina S. Kjellson sold 27,493 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $16.56, for a total value of $455,284.08. Following the completion of the transaction, the director now owns 458,506 shares of the company’s stock, valued at approximately $7,592,859.36. This represents a 5.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 101,050 shares of company stock valued at $2,235,492 over the last ninety days. Corporate insiders own 15.40% of the company’s stock.

Tyra Biosciences Price Performance

Shares of NASDAQ:TYRA opened at $15.36 on Friday. The stock has a market cap of $777.22 million, a P/E ratio of -9.62 and a beta of 1.08. Tyra Biosciences, Inc. has a 1-year low of $10.60 and a 1-year high of $29.60. The firm has a fifty day moving average price of $21.00 and a 200 day moving average price of $19.92.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Sell-side analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.